China's Biotech Revolution

July 1, 2019 06:30

Last year, 30% of all investments into US biotech start-ups came from Chinese venture funds; the Hong Kong Stock Exchange issued its first pre-commercial biotech IPOs; and US regulators for the first time approved a new cancer drug developed by a Chinese company. How will the rise of China as a biotech powerhouse affect the global biotech industry?

This session was developed in partnership with Scientific American.

Simultaneous interpretation in English, Mandarin Chinese and Japanese

This session will be livestreamed on TopLink and the Forum website.

Speakers:

Cong Yali

Professor; Dean, Department of Medical Ethics and Health Law, Peking University

Mariette DiChristina

Dean, College of Communication, Boston University

Xu Xun

President, Research, BGI

Jackson Zhu Weiyan

Chief Executive Officer and Founder, My Bio-Med